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Abstract
Background: FOXE1 is one of the candidate genes for genetic predisposition to premature ovarian failure (POF)
and it contains an alanine tract. Our purpose is to assess the influence of length of the alanine tract of FOXE1 on
genetic susceptibility to POF.
Methods: The group studied consisted of 110 Chinese patients with idiopathic POF and 110 women from normal
controls. The polyalanine tract and flanking sequence of FOXE1 was screened using the Multiple Ligation-
dependent Probe Amplification (MLPA) technique and directly sequenced.
Results: Three variants of FOXE1-polyalanine length, containing 12, 14, or 16 alanine residues, and 5 different
genotypes were identified. There were significantly lower frequencies of the 14/14 genotypes in cases with POF
(X2 = 119.73, P = 0.001), as compared with the controls. The incidence of 16/16 genotypes of FOXE1-polyalanine
was significantly higher in patients with POF (X2 = 3.403, P = 0.001) in comparison to the controls. The FOXE1 14
alanine allele was significantly less common in the POF patient group (186/220) than the controls (216/220) (X2 =
25.923, P = 0.0001). The FOXE1 16 alanine allele was significantly more common in the POF patient group (28/220)
than the controls (4/220) (X2 = 19.412, P = 0.0001).
Conclusion: This finding provides evidence that polyalanine repeat expansions in FOXE1 may be responsible for
the genetic aetiology of POF in Chinese women.
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Background
The diagnosis of premature ovarian failure (POF) is
based on the finding of amenorrhea before the age of 40
years associated with follicle-stimulating hormone levels
in the menopausal range. It is a common disease affect-
ing approximately 1% of women <40 years, 1:10,000
women by age 20 years and 1:1,000 women by age 30
years [1]. POF is generally characterized by low levels of
gonadal hormones and high levels of gonadotropins (LH
and FSH). POF is a heterogeneous disorder determined
by many pathogenic mechanisms [2]. The principal
causes of POF are chromosomal, genetic, autoimmune,
metabolic, infectious, and iatrogenic. A large proportion
of cases remain without a known cause, and these are
classified as idiopathic or karyotypically normal sponta-
neous premature failure [2].
In the last 2 decades, many studies using molecular
biology technology aimed to discover a relationship
between POF and genetic disorders [3-6]. POF has
recently been associated with mutations in Forkhead L2
(FOXL2) gene, which is associated with blepharophimo-
sis-ptosis-epicanthus inversus (BPES) syndrome [7].
BPES is a rare autosomal dominant disease with a pre-
valence of about 1 in 50,000. Clinically, BPES has been
divided into two subsets depending on the association
of ocular malformation with (type I) or without (type II)
POF. Genetically, however, both types are caused by
mutations in FOXL2, and a genotype-phenotype correla-
tion has been described in some cases [8].
FOXL2 belongs to the large family of forkhead (FOX)
transcription factors which encodes a transcription fac-
tor containing a forkhead domain for DNA-binding and
a polyalanine domain of uncertain function. Members of
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this family are expressed in a wide range of tissues, are
involved in a variety of developmental processes and are
thought to play an important role in mediating trans-
forming growth factor (TGF) superfamily signals by
binding to members of the Smad family of proteins [9].
Following the discovery of FOXL2 polyalanine tract
deletions in POF patients [10,11], it was important to
study other forkhead genes with a polyalanine tract in
order to determine whether changes in this region
might also be associated with POF. FOXE1 consists of a
single exon that codes for a forkhead domain, a polyala-
nine tract, and unique C-terminal residues. Initially, the
polyalanine tract was reported to consist of 19 residues
[12]. Subsequently, the length of the major alanine
stretch was shown to be 14 residues [13]. Patients carry-
ing homozygous mutations in FOXE1 present athyroidal
hypothyroidism, spiky hair, choanal atresia, cleft palate
and bifid epiglottis, known as Bamforth-Lazarus syn-
drome [14]. Polymorphism of the polyalanine tract of
FOXE1 was reported for the first time by Macchia et al.
with variable length from 12 to 17 alanines [13]. How-
ever, it is noteworthy that frequency of alleles is quite
different among the different control groups, even
among the same population [13,15]. A few studies have
pointed to the potential role of FOXE1-polyalanine
length polymorphism in determining the susceptibility
to POF [16]. However, the evaluation of its length in
chinese patients with POF has not been conducted so
far. Hence, the objective of the present study was to
assess the influence of the FOXE1-polyalanine length on
susceptibility to POF in Chinese women, using the Mul-
tiple Ligation-dependent Probe Amplification (MLPA)
technique, which is one of the best methods for detect-
ing alterations in gene dosage [17].
Methods
Patient and control recruitment
One hundred and ten patients with idiopathic POF were
recruited between January 2009 and July 2010 at the
Affiliated Shenzhen City Maternity and Child Healthcare
Hospital of Southern Medical University, Shenzhen, PR
China. The study was approved by the University’s Insti-
tutional Ethics Committee and informed consent was
obtained from all participants. The diagnostic criteria
for POF was as follows: at least 6 months of amenor-
rhoea before the age of 40, with at least two serum FSH
concentrations of >40 IU/l. Controls (n = 110) were
individuals under 40 with proven fertility, normal men-
strual cycles, normal FSH levels and ovary morphology,
with no history of subfertility treatment. Each patient
and control were assessed clinically, with a complete
medical and gynecological history, including the history
of menses, age at menopause, LH and FSH levels (two
times at one-month intervals), T3,T4 and TSH levels,
and pelvic ultrasound. Patients with associated endocri-
nopathies, autoimmune disorders, iatrogenic agents,
such as pelvic surgery, chemotherapy, and radiotherapy,
and infections, were excluded. The controls were
recruited from the health examination department of
the Affiliated Shenzhen City Maternity and Child
Healthcare Hospital of Southern Medical University,
matched by sex and age. In the control group, tumor,
endocrinopathies, autoimmune disease, and infections
were excluded. Karyotyping with high-resolution GTG
banding to check for chromosomal anomalies was per-
formed in all patients and controls. Those with abnorm-
alities were excluded from the study.
DNA extraction and karyotyping
A 5 ml aliquot of peripheral blood was collected in
EDTA vacutainers for genomic DNA isolation, and
another 5 ml of peripheral blood was collected in
heparin vacutainers for chromosomal analysis. Genomic
DNA was extracted from lymphocytes using standard
proteinase K/chloroform extraction methods [18]. Chro-
mosomal analysis was performed on phytohaemaggluti-
nin (PHA)-stimulated peripheral lymphocyte cultures
using standard conventional cytogenetic methods.
PCR
The FOXE1 (Swiss-Prot: O00358) coding sequence,
flanking the polyalanine tract, was amplified using stan-
dard polymerase chain reaction (PCR) conditions. The
following primers, designed to border polyalanine tract,
were used : forward (F): 5´-CTTCAAGCGCTCG-
GACTCTC-3´ and reverse (R): 5´-ACGCCGCGGGG-
TAGTAGACTG-3´. The position of the primers was
c.444-c.749.The amplicons (194 bp to 212 bp,12-18 ala-
nines) were purified. After 4 min of initial denaturation
at 95°C, 40 cycles of PCR were performed , followed by
7 min of final extension at 72°C. Each cycle included:
denaturation 30 s at 95°C, annealing 30 s at 64°C, and
elongation 30 s at 72°C. PCR was performed in 25 μl
volume of reaction mixture, with the following reagents
concentrations: 2.5 μl of 10×PCR buffer with Mg, 5 μl
of GC-rich solution, 2.5 μl of dNTP at a final concentra-
tion of 200 μM, 0.2 μl of Fast Start Taq Polymerase
(Roche Diagnostics, Mannheim, Germany), 2 μl of DNA
(150 ng), 1 μl of primers (F+R, final concentration of 1
μM) and 11.8 μl of nuclease-free water.
MLPA Analysis
All the MLPA reagents come from MRC-Holland
(Amsterdam the Netherlands). The hybridization and
ligation of probes were performed in Biosystems 2720
thermal cycler according to the standard MLPA proto-
col. pCYF (5´CACGACGTTGTAAAACGACCTT-
CAAGCGCTCGGACCTCTC-3´) and pCYR (5´-
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ACGCCGCGGGGTAGTAGACTG-3´) were used as
universal PCR primers in the ligated probes amplifica-
tion. The length of amplicons obtained ranged from 213
bp (corresponding to 12-alanine polyalanine) to 231 bp
(corresponding to 18-alanine polyalanine). 250 ng DNA
of each patient was denatured for 5 min at 98°C and
hybridized overnight at 60°C with the SALSA probe mix
pCYF and pCYR. The hybridization products were sub-
sequently treated with a ligase enzyme for 15 min at 54°
C. The ligation reaction was stopped by raising the tem-
perature for 5 min at 98°C. Finally, PCR amplification
was carried out with the specific SALSA FAM primers
using the ligation product as templates. PCR products
were checked on a 2% agarose gel and subsequently
resolved by capillary electrophoresis on an ABI PRISM
3130. The data were analyzed by the Gene Marker ver-
sion 1.6 software.
All PCR products were obtained using the above-men-
tioned primers, amplifying the polyalanine tract and
flanking regions of the gene. Samples were sequenced
using BigDye Terminator Cycle Sequencing Kit 3.1
(Applied Biosystems, USA) with the above primers, and
run on a 3730 × l ABI DNA Analyzer (Applied Biosys-
tems). The sequencing results were analyzed using
Chromas (version 2.3) and compared with reference
sequences in the National Center for Biotechnology
Information (NCBI) database.
Statistical analysis
Chi-square test was performed using SPSS 13.0 Software
(SPSS Inc., Chicago, IL). We used two-sided Fisher’s
exact test to compare Ala polymorphisms between POF
and controls.
Results
Clinical characteristics of the population
One hundred and ten Chinese patients with idiopathic
POF and 110 women from normal controls completed
the study. Mean age was 31.58 ± 6.02 years (18-39) in
the POF patients and 30.43 ± 4.02 years (20-39) in the
controls. Most of our patients (105/110; 95.5%) pre-
sented with normal puberty and secondary amenorrhea,
and only 5 (4.5%) displayed primary amenorrhea.
Sequence variants detected in FOXE1
Assessment of the FOXE1-polyalanine length was per-
formed for the patients with POF and the control
group. In the population studied, FOXE1-polyalanine
was polymorphic in both groups. Three variants of
FOXE1-polyalanine length, containing 12, 14, or 16 ala-
nine residues, and 5 different genotypes were identified
(Table 1). The most common genotypes were 14/14
homozygote, occurring with the frequency of 81.2 % in
the POF group, while 96.4% in control subjects,
respectively. There were significantly lower frequencies
of the 14/14 genotypes in cases with POF (c2 = 119.73,
P = 0.001), as compared with the controls. The homozy-
gote for 16/16 residues was identified in 10.0% of the
patients with POF, but was not found in control sub-
jects. Compared with controls, there were significantly
higher frequencies of the 16/16 genotypes in cases with
POF (c2 = 3.403, P = 0.001). The heterozygote for 14/16
residues was identified in 2.7% of the patients with POF,
but also in 3.6% of the control subjects. The rare 12/14
heterozygous FOXE1 variant as well as the 12/16 homo-
zygous variant were only detected in POF subjects with
a frequency of 2.7%, but was not found in control
subjects.
Fisher’s exact test was used to compare individual
allele frequencies between POF and controls. The
FOXE1 14 alanine allele was significantly less common
in the POF patient group (186/220) than the controls
(216/220) (c2 = 25.923, P = 0.0001). The FOXE1 16 ala-
nine allele was significantly more common in the POF
patient group (28/220) than the controls (4/220) (c2 =
19.412, P = 0.0001).
Bonferroni’s adjustment to an overall significance level
of 0.05 was used as the cutoff value (i.e., a = 0.05/n,
where “n” is the number of tested). Finally, the use of
arbitrary a priori P value cutoffs in conjunction with
Bonferroni’s correction proved useful in the analysis of
microarray data [19], so data in this study was also
examined at two P values, 0.010 for genotypes frequency
analysis and 0.016 for allele frequency analysis. After
Bonferroni’s adjustment for multiple statistical analyses,
Table 1 Percentage of identified FOXE1 genotypes
frequency in patients with premature ovarian failure
(POF) and a control group
Genotypes POF n (%) Controls n (%) c2 P
14/14 90(81.2) 106(96.4) 119.73 0.001a
16/16 11(10.0) 0(0) 3.403 0.001 a
12/14 3(2.7) 0(0) 3.041 0.247
12/16 3(2.7) 0(0) 3.041 0.247
14/16 3(2.7) 4(3.6) 0.148 1.000
a P Value remains significant after Fisher’s exact test with Bonferroni’s
correction for multiple testing: p value = 0.010.
Table 2 Percentage of identified FOXE1 allele frequency
in patients with premature ovarian failure (POF) and a
control group
Allele POF n (%) Controls n (%) c2 P
12 6(2.7) 0(0) 6.083 0.0300
14 186(84.5) 216(98.2) 25.923 0.0001 a
16 28(12.7) 4(1.8) 19.412 0.0001 a
a P Value remains significant after Fisher’s exact test with Bonferroni’s
correction for multiple testing: p value = 0.016.
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the above findings remain significant. The total distribu-
tion of different alleles is summarized in Table 2.
The preferred screening approach was to use MLPA
to size the different alleles. Pherograms displaying the
MLPA output of the five different FOXE1 genotypes
were shown in Figure 1.
These reduced polyalanine residues of 496-510del
(AAAAA166-170del), 505-513del(AAA169-171del), and
541-546del(AA181-182del) were detected in the patients
with POF and the control group. Three types of missing
alanine residues were shown in Figure 2.
Discussion
Alanine-tract expansions in transcription factors have
been implicated as a cause of some human diseases. The
polyalanine tract length of FOXE1 is of interest as
FOXL2, a gene commonly mutated in BPES and more
recently found to be altered in patients with isolated
POF, contains a highly conserved polyalanine tract
[8,11]. FOXE1 is located at 9q22 and the single exon
gene encodes a forkhead domain, a polyalanine tract,
and unique C-terminal residues. It is thought to be
involved in thyroid morphogenesis. Mutations in FOXE1
cause Bamforth-Lazarus Syndrome. FOXE1 polyalanine
tract length has not been specifically correlated with
these thyroid dysfunctions [20]. However, it is possible
that certain alleles, or certain alleles in combination, are
linked to a higher risk of thyroid complications. It was
noted that between 10 and 20% of women with POF
have an autoimmune disease, most commonly hypothyr-
oidism [21]. FOXE1 is therefore an appropriate gene to
investigate, in order to identify more genetic causes of
POF. The length of FOXE1 -polyalanine reported in this
study varied from 12 to 16 alanines, compared to pre-
vious reports [13,16,22,23] where a total number of ala-
nine coding triplets ranged from 11 to 19. The observed
inconsistency could be at least partially explained with
ethnic differences of polyalanine tract variations.
To date, polyalanine tract expansions in transcription
factors have been reported as a molecular factor of
numerous diseases and elongation of the tract was con-
nected with higher morbidity, a more severe clinical pic-
ture and poorer prognosis [24]. On the other hand,
polyalanine tract contractions have not been involved
with certainty in the etiopathogenesis of human diseases
[25].A computer program that predicts protein second-
ary structure [26] indicated that the polyalanine tract of
FOXE1 constitutes an a-helical region C-terminal to the
Figure 1 Analysis of FOXE1-polyalanine length with the use of
Multiple Ligation-dependent Probe Amplification (MLPA)
technique. Pherograms displaying the MLPA output of the five
different FOXE1 genotypes. In the Y-axis are depicted the intensity
signals (peak heights) for probe that are depicted in the X-axis
according to their length (probe size).
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forkhead domain. In several transcription factors which
repress the transcription of target genes, alanine-rich
regions, which form a-helical regions and are responsi-
ble for the transcriptional repression, were identified
[27,28]. Alanine expansion may lead to disturbances in
protein conformation and potentially affect the process
of transcription regulation by impairing specific binding
to DNA.
In this study of 110 Chinese population with idio-
pathic POF, we detected no mutations of the FOXE1
gene other than an already known silent single nucleo-
tide polymorphism and polymorphic expansions or con-
tractions of the alanine-encoding nucleotide triplets that
lead to variations of the length of alanine tracts within
the polyalanine domain of the FOXE1 gene product.
Recently, in the study on a Poland population by Szcze-
panek et al [29], the incidence of longer variants (≥16
codons) of FOXE1-polyalanine was significantly higher
in patients with the familial form of thyroid hemiagen-
esis(TH) in comparison to those with sporadic TH. Our
finding of polymorphisms is in accordance with the stu-
dies from Watkins et al [16]. We found that the homo-
zygous Ala14 polymorphism (Ala14/14) was less
frequent in the POF group than in the controls. In con-
trast, significantly more POF patients than controls har-
bored the Ala16 polymorphism(Ala16/16). Indeed,
patients affected by POF present a significantly lower
proportion of the 14/14 genotype compared to controls
(81.2% vs. 96.4%). Thus, POF is associated with the
more common variant (allele 16) suggesting that the
more common variant (allele 16) may increases the risk
of developing POF. Our results suggest that the length
of the alanine stretch within FOXE1 modulates genetic
susceptibility to POF. Interestingly, we have discovered
three different reduced polyalanine residues which make
up the 12-16 alanine FOXE1 alleles leading us to specu-
late that different mechanisms have operated to bring
about these contractions and expansions. The lack of a
variation in the Chinese population of the alleles (17, or
19) is interesting, as we assume that this is from a rela-
tively homogenous population, and is similar to what is
seen in the Japanese population [20], but not in some of
the New Zealand populations [16] studied to date.
These difference might reflect ethnicity-related
deviations.
Previous studies employed direct sequencing [29] and
DHPLC [16] for analysis of FOXE1-polyalanine length
polymorphism, while in our study an analysis of DNA
fragment length was performed with MLPA. Major
drawbacks of the DHPLC method are chemical waste,
high maintenance cost, the need for post-PCR manipu-
lations, and low throughput [30]. Unlike DHPLC, MLPA
is a recently developed semi-quantitative method that
aims to detect copy number alterations at the genomic
level (gains or loses) in a test DNA with respect to a
control. Due to its low cost, reliability and ease of
implementation it has become very popular both as a
research and a diagnostic tool [31]. This appeared to be
a useful method for the evaluation of polyalanine tract
expansions as its consistency with direct bilateral
sequencing results was confirmed for selected samples.
Moreover, interpretation of sequences obtained in direct
sequencing from heterozygous patients is a difficult and
mistake-prone method, while MLPA is unequivocal and
easy (Figure 1). As until now this technique have not
been reported to screen the FOXE1 gene, we applied
the usefulness of MLPA as a method to detect sequence
alterations in the polyalanine tract of FOXE1.
Conclusions
To sum up, the present study confirmed a high hetero-
geneity of the number of alanine residues in FOXE1 in
the population studied. The heterogeneity was identified
even among the control subjects, therefore indicating
polymorphic variability and a rather weak impact on
phenotype. However, A significant difference in geno-
type and allele frequencies were noted between the two
groups, which can be attributed to the increased
Figure 2 Nucleotide sequence and its corresponding amino acid sequence for the FOXE1 gene around the polyalanine tract. 496-
510del (AAAAA166-170del) is shown by underlining, 505-513del (AAA169-171del) is shown by [ ], and 541-546del (AA181-182del) is shown by ().
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frequency of 16/16 homozygotes in the POF group.
There is no evidence for an increase in heterozygous
carriers of the 16 allele suggesting this affects suscept-
ibility in a recessive manner. The results obtained sug-
gest that alteration from the most frequently occurring
14 alanine allele to the 16 allele increases the risk of
developing POF, therefore FOXE1-polyalanine tract
expansion may contribute to the molecular background
of POF. Still, the number of patients studied sets limits
in the interpretation of the results obtained, the same as
does the fact that no molecular study has been per-
formed to support the functional significance of
FOXE1-polyalanine length polymorphism. More
research is required to confirm such findings.
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